03:21 AM EDT, 08/06/2026 (MT Newswires) -- Evotec (EVT.F) is collaborating with clinical-stage biopharmaceutical company Odyssey Therapeutics on a research initiative for new autoimmune and inflammatory disease treatments. The companies are looking to discover and validate differentiated small-molecule drug candidates for a variety of disease targets through the partnership, according to a Thursday filing. The German life science company will be entitled to milestone payments for each successful delivery of a validated hit series for each disease target.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.